Hot off the Forge
-
John Maslowski, Chief Commercial Officer, to succeed Dr. Timothy Miller as President and CEO. “It’s an exciting time at Forge.”
-
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon…
-
“As we continue to advance how genetic medicines are manufactured, we are thrilled to present data showcasing our novel molecular…
-
Designation grants Forge’s FBX-101 therapy access to enter the Innovative Licensing and Access Pathway (ILAP).
-
Five patients have received FBX-101, all of whom were identified by newborn screening.
-
Research findings indicate a path to the development of potentially safer adeno-associated virus (AAV) gene therapies.
-
Acquisition positions Forge for accelerated long-term growth supporting gene and cell therapy clients worldwide.
-
Forge joins the CIRM Industry Resource Partner Program and will enable accelerated research and cGMP AAV manufacturing to CIRM-funded programs.
-
Forge will be delivering presentations, participating in fireside chats, and taking one-on-one meetings at four September investor conferences.
-
“Forge has proven to be a trusted partner to many gene therapy developers.”
-
Christopher Shilling to represent Forge on the BGTC’s Steering Committee, which will work towards speeding the process of gene therapy…
-
Forge’s presentations at the Meeting of the American Society of Gene and Cell Therapy highlight cell line and plasmid developments.